Aerovate Therapeutics Inc (AVTE)

$2.68 0.00 (N/A)
Market Cap 77.68M
Revenue (ttm) 0.00
Net Income (ttm) -69.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,027,900
Avg Vol 306,224
Day's Range N/A - N/A
Shares Out 28.99M
Stochastic %K 38%
Beta 0.95
Analysts Hold
Price Target $2.50

Company Profile

Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 617 443 2400
Address:
930 Winter Street, Suite M-500, Waltham, United States
Latest News on AVTE
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million

Apr 28, 2025, 10:18 AM EDT - 2 months ago

Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million

Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

Apr 21, 2025, 8:00 AM EDT - 2 months ago

Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

Apr 9, 2025, 4:05 PM EDT - 2 months ago

Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

Apr 7, 2025, 8:30 AM EDT - 2 months ago

Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE

Mar 21, 2025, 11:30 AM EDT - 3 months ago

AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders

Nov 1, 2024, 12:02 PM EDT - 8 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders

PFIE

Aerovate Therapeutics to Explore Strategic Alternatives

Jul 8, 2024, 8:00 AM EDT - 1 year ago

Aerovate Therapeutics to Explore Strategic Alternatives

Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC

Jun 21, 2024, 2:00 PM EDT - 1 year ago

Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC

Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm

Jun 20, 2024, 1:22 PM EDT - 1 year ago

Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

Jun 17, 2024, 8:32 AM EDT - 1 year ago

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Jun 11, 2024, 1:19 PM EDT - 1 year ago

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference

May 21, 2024, 4:15 PM EDT - 1 year ago

Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

May 13, 2024, 4:30 PM EDT - 1 year ago

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference

Mar 27, 2024, 9:20 AM EDT - 1 year ago

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

Mar 25, 2024, 4:10 PM EDT - 1 year ago

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

Mar 6, 2024, 8:00 AM EST - 1 year ago

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

Nov 20, 2023, 4:45 PM EST - 1 year ago

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights

Nov 13, 2023, 8:00 AM EST - 1 year ago

Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights

Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights

Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

Jul 11, 2023, 5:00 PM EDT - 2 years ago

Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

Aerovate: Smart Investment Opportunity With This Developer Of Inhaled Imatinib For PAH

Jun 28, 2023, 8:00 AM EDT - 2 years ago

Aerovate: Smart Investment Opportunity With This Developer Of Inhaled Imatinib For PAH

Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference

Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference

May 22, 2023, 1:15 PM EDT - 2 years ago

Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

May 15, 2023, 4:05 PM EDT - 2 years ago

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market

Apr 12, 2023, 8:45 AM EDT - 2 years ago

Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market

Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights

Mar 29, 2023, 4:50 PM EDT - 2 years ago

Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights

Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference

Mar 2, 2023, 8:00 AM EST - 2 years ago

Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference

Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy

Jan 29, 2023, 7:12 AM EST - 2 years ago

Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy

Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

Jan 23, 2023, 8:00 AM EST - 2 years ago

Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

Nov 17, 2022, 7:45 AM EST - 2 years ago

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

Aerovate Therapeutics Announces Third Quarter 2022 Financial Results

Nov 14, 2022, 7:45 AM EST - 2 years ago

Aerovate Therapeutics Announces Third Quarter 2022 Financial Results

Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022

Oct 18, 2022, 8:00 AM EDT - 2 years ago

Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022

Aerovate Therapeutics Announces Second Quarter 2022 Financial Results

Aug 15, 2022, 7:50 AM EDT - 3 years ago

Aerovate Therapeutics Announces Second Quarter 2022 Financial Results

Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

May 16, 2022, 5:15 PM EDT - 3 years ago

Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

Aerovate Therapeutics Announces First Quarter 2022 Financial Results

May 16, 2022, 8:00 AM EDT - 3 years ago

Aerovate Therapeutics Announces First Quarter 2022 Financial Results

Aerovate Therapeutics Announces Full-Year 2021 Financial Results

Mar 30, 2022, 4:45 PM EDT - 3 years ago

Aerovate Therapeutics Announces Full-Year 2021 Financial Results

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

Dec 15, 2021, 8:00 AM EST - 3 years ago

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

Aerovate Therapeutics Announces Third Quarter 2021 Financial Results

Nov 15, 2021, 8:00 AM EST - 3 years ago

Aerovate Therapeutics Announces Third Quarter 2021 Financial Results

Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index

Sep 17, 2021, 8:00 AM EDT - 4 years ago

Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index

Aerovate Therapeutics Announces Second Quarter 2021 Financial Results

Aug 16, 2021, 8:00 AM EDT - 4 years ago

Aerovate Therapeutics Announces Second Quarter 2021 Financial Results

Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Jul 2, 2021, 4:01 PM EDT - 4 years ago

Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Drug Formulation Developer Aerovate Therapeutics Kick Starts Trading Today With Upsized Debut

Jun 30, 2021, 3:37 PM EDT - 4 years ago

Drug Formulation Developer Aerovate Therapeutics Kick Starts Trading Today With Upsized Debut

Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering

Jun 29, 2021, 10:59 PM EDT - 4 years ago

Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering

Aerovate Therapeutics Readies $100 Million IPO Effort

Jun 28, 2021, 8:00 PM EDT - 4 years ago

Aerovate Therapeutics Readies $100 Million IPO Effort